OnDosis
- Martin Olovsson
Martin Olovsson has a diverse range of work experience. Martin is currently the CEO and co-founder of OnDosis, where they aim to revolutionize medication dosing through the combination of pharmaceuticals and technology. Martin also serves as a Board Member for AQILION AB, WntResearch AB, and ScientificMed, contributing their expertise to these companies. In the past, Martin worked at AstraZeneca in various roles, including Global VP Inhaled Respiratory franchise and Marketing Company President. Additionally, they have served as a Board Member for The Swedish Association of the Pharmaceutical Industry, LIF.
Martin Olovsson completed their education with the following chronology of academic pursuits:
From 2013 to 2014, they attended the Transformational Leadership Program and Executive Program at Harvard Business School Executive Education.
In 2002, Martin Olovsson attended The Wharton School, where they focused on Leading the Effective Salesforce.
Between 1988 and 1992, they pursued a Bachelor of Science degree in Business Administration and Management, General at Lund University.
Lastly, Martin Olovsson earned an Engineer's degree in Electronics from Tycho Braheskolan, graduating in the period of 1983 to 1987.
Location
Gothenburg, Sweden
Links
Previous companies
Org chart
Upgrade to view 22 reports
Offices
OnDosis
OnDosis proprietary technology delivers flexible and individualized dosing of oral medicines formulated as micro units. They are focused on providing reassurance in disease management, supporting adherence and providing greater convenience for patients. OnDosis is currently developing products for individualized dosing in diseases with asignificant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes.The flexibility of OnDosis technology provides the potential for application across several disease areas and patient segments where conventional tablets or capsules often does not provide a good fit for the patient or treatment goal.OnDosis was founded in 2017 and is headquartered in Gothenburg, Sweden, based on an idea that was spun-out from AstraZeneca, using technology based on development work initiated there. It was founded by GU Ventures and Martin Olovsson. OnDosis operates a network of strategic partners across all core functions including formulation and device development, IP, Regulatory and Business Development.
Ad